 |
12 Diseases |  |
17 Trials |
|
17 Trials |  |
2487 News |  |
| «12...1112131415161718192021...2425» |
- ||| Aimovig (erenumab) / Amgen, Novartis
Clinical: It looks like the EU will form a conclusion about licencing Aimovig for 6-18 yos in 2026. Here's where they set out the research being undertaken - evidently they are still seeing if it's safe for that population. https://t.co/u0bWa0Ve1q (Twitter) - Dec 14, 2020
- ||| Aimovig (erenumab) / Amgen, Novartis
@MigraineTrust does this mean it is possible to have off label privately paid cGRP treatment in the UK for adolescents @petergoadsby please? @PutAimovigOnNHS (Twitter) - Dec 13, 2020
- || Reyvow (lasmiditan) / Eli Lilly
PK/PD data, Review, Journal: Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. (Pubmed Central) - Dec 9, 2020
In the case of monoclonal antibodies, the issue of pharmacodynamic interactions related to the modulation of the immune system functions was addressed. It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR).
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New trial: MicroRNA Profile and Erenumab Treatment (clinicaltrials.gov) - Dec 8, 2020
P=N/A, N=40, Not yet recruiting, Sponsor: University of L'Aquila
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) - Dec 8, 2020
P1, N=60, Recruiting, Sponsor: Amgen
It also focuses on the effect of monoclonal antibodies on expression of class Fc gamma receptors (FcγR). Trial completion date: Sep 2021 --> Dec 2021
- ||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: A Controlled Trial of Erenumab in Migraine Prevention (clinicaltrials.gov) - Nov 30, 2020
P3, N=261, Completed, Sponsor: Amgen
Trial completion date: Sep 2021 --> Dec 2021 Active, not recruiting --> Completed
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Design and patient population of the first randomized, double-blinded Double-dummy study of erenumab and topiramate for the prevention of episodic and chronic migraines () - Nov 29, 2020 - Abstract #DGN2020DGN_1223;
Active, not recruiting --> Completed The analysis will provide insights into the patient population included in the first direct comparative study on the tolerability and efficacy of erenumab vs. Topiramate was included.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Analysis of a patient population with regard to long-term safety and tolerability of the monoclonal antibody erenumab and the frequency of Medication breaks according to the German treatment algorithm () - Nov 29, 2020 - Abstract #DGN2020DGN_1222;
P4
APOLLON is a 128-week open study on treatment with erenumab, in which long-term data on the safety and tolerability of migraine patients in Germany who previously participated in a direct comparative study on the tolerability of erenumab and topiramate are evaluated (NCT03828539). This analysis will provide insights into the patient population that will be observed at around 80 German headache centers to evaluate the long-term safety and tolerability of erenumab, as well as the frequency and timing of drug breaks during erenumab treatment.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] The importance of the attitude of the patient and the attending physician in the assessment Comprehensive real-world evidence on migraine prophylaxis with erenumab () - Nov 29, 2020 - Abstract #DGN2020DGN_1220;
These analyzes show differences and overlaps in the perception of the success of migraine treatment with erenumab by patients and physicians. The comparison makes it clear how important it is to understand the limitations of the surveyed population and thus shows that only considering both Pages comprehensive, realistic statements about the value of a treatment.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Characterization of the use of the monoclonal antibody erenumab in the daily clinical routine in Germany from the perspective of the attending physician () - Nov 29, 2020 - Abstract #DGN2020DGN_1219;
The comparison makes it clear how important it is to understand the limitations of the surveyed population and thus shows that only considering both Pages comprehensive, realistic statements about the value of a treatment. The TELESCOPE study provides real-world data on the therapy of erenumab in Germany, typical patient profiles and the effects of the therapy on everyday life and quality of life of the patients.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] First data collection on the use of prophylactic migraine treatments including the monoclonal antibody erenumab from the patient's perspective () - Nov 29, 2020 - Abstract #DGN2020DGN_1218;
The TELESCOPE study provides real-world data on the therapy of erenumab in Germany, typical patient profiles and the effects of the therapy on everyday life and quality of life of the patients. PERISCOPE provides us with the first "real-world" data from German patients who were treated with erenumab and shows that patients benefit from erenumab treatment in terms of improving quality of life and reducing migraine-specific symptoms.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Characterization of the pattern of prescribing erenumab in patients with episodic or chronic migraines in Germany () - Nov 29, 2020 - Abstract #DGN2020DGN_1217;
The SPECTER study will provide valuable insights into the clinical routine of erenumab prescriptions in Germany. The characterization of the prescription pattern and the analysis of the respective therapy response will make it possible to develop individual treatment strategies for each patient Develop.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: Characterization of the use of the monoclonal antibody erenumab in daily clinical routine in Germany from the perspective of the attending physician () - Nov 28, 2020 - Abstract #DGN2020DGN_620;
- [VIRTUAL] Therapy-refractory patients with chronic migraines and daily headaches: real-world experiences of treatment with CGRP antibodies () - Nov 28, 2020 - Abstract #DGN2020DGN_618;
CGRP (receptor) antibodies appear at least for some patients with chronic migraines and Persistent headache to be an effective treatment option. Further research needs these initial results confirm both in the longer-term course and in a larger cohort.
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: Design and patient population of the first randomized, double-blind, double-dummy study with erenumab and topiramate for the prevention of episodic and chronic migraines () - Nov 28, 2020 - Abstract #DGN2020DGN_617;
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Treatment of migraine patients with erenumab among the Supply conditions in Germany: results from the NTD headache and Migraine database () - Nov 28, 2020 - Abstract #DGN2020DGN_616;
The effect on the responder rate increased over three applications and remained largely constant over the duration of the application. In this respect, the results confirm the recommendations of the DGN and DMKG guidelines until the effectiveness is assessed three months to treat 1 .
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: Analysis of a patient population with regard to long-term safety and tolerability of the monoclonal antibody erenumab and with regard to the frequency of drug breaks according to the German treatment algorithm () - Nov 28, 2020 - Abstract #DGN2020DGN_608;
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: Characterization of the prescription pattern for erenumab in patients with episodic or chronic migraine in Germany () - Nov 28, 2020 - Abstract #DGN2020DGN_606;
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: The importance of the attitudes of the patient and the treating physician in the assessment of comprehensive real-world evidence data on migraine prophylaxis with erenumab () - Nov 28, 2020 - Abstract #DGN2020DGN_605;
- Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Industry poster: First data collection on the use of prophylactic migraine treatments including the monoclonal antibody erenumab from the patient's perspective () - Nov 28, 2020 - Abstract #DGN2020DGN_604;
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Aimovig (erenumab) / Amgen, Novartis
[VIRTUAL] Erenumab therapy in a patient with MELAS syndrome and migraine - one case () - Nov 28, 2020 - Abstract #DGN2020DGN_602;
Prophylactic treatment with erenumab was started early after stroke-like episode started. The effectiveness of therapy with erenumab was convincing; it came after discontinuation rapidly worsening headache again.
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: APOLLON: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (clinicaltrials.gov) - Nov 26, 2020
P4, N=682, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
The effectiveness of therapy with erenumab was convincing; it came after discontinuation rapidly worsening headache again. Recruiting --> Active, not recruiting
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Aimovig (erenumab) / Amgen, Novartis
Observational data, Journal: Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study. (Pubmed Central) - Nov 21, 2020
Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p = .006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.
- || TEV-48125 / Teva, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Clinical Experience with Calcitonin Gene-Related Peptide (CGRP) in Patients with Post-Concussion Headaches. (Pubmed Central) - Nov 19, 2020
Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia. CGRP Antagonists show potential to be a useful approach for the management of post-concussion headaches.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal, HEOR, Real-World Evidence: Erenumab in highly therapy-refractory migraine patients: First German real-world evidence. (Pubmed Central) - Nov 18, 2020
CGRP Antagonists show potential to be a useful approach for the management of post-concussion headaches. Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
New trial: CGRP-1: CGRP Inhibition, Autonomic Function, and Migraine (clinicaltrials.gov) - Nov 12, 2020
P, N=120, Recruiting, Sponsor: Medical University of Vienna
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. (Pubmed Central) - Nov 12, 2020
P2
Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients. In this long-term study of a CGRP-receptor antibody, erenumab was found to be safe and well-tolerated with a spectrum and rate of adverse events consistent with shorter-term placebo-controlled studies.
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion date: RESET BRAIN: A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients (clinicaltrials.gov) - Nov 10, 2020
P4, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
In this long-term study of a CGRP-receptor antibody, erenumab was found to be safe and well-tolerated with a spectrum and rate of adverse events consistent with shorter-term placebo-controlled studies. Trial completion date: Feb 2021 --> May 2021
- ||| Aimovig (erenumab) / Amgen, Novartis
Nuevos datos de @Novartis sobre Aimovig frente a topiramato en #migraña - https://t.co/lWEGflTEuj (Twitter) - Nov 4, 2020
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, Enrollment open: INTERROGATE: Biomarker and Genetic Predictors of Erenumab Treatment Response (clinicaltrials.gov) - Nov 4, 2020
P4, N=2000, Recruiting, Sponsor: Amgen
Trial completion date: Feb 2021 --> May 2021 Not yet recruiting --> Recruiting
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Efficacy and safety of erenumab in women with a history of menstrual migraine. (Pubmed Central) - Nov 3, 2020
P3
Not yet recruiting --> Recruiting Data from this subgroup analysis of women with menstrual migraine are consistent with data from the overall STRIVE episodic migraine population, supporting the efficacy and safety of erenumab in women who experience menstrual migraine.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. (Pubmed Central) - Nov 2, 2020
Erenumab inhibits calcitonin gene-related peptide-induced vasodilatory responses in human middle meningeal arteries, human internal mammary arteries and human coronary arteries. Moreover, erenumab shows functional specificity as no interaction was observed with the relaxant responses to several vasodilators, nor the dihydroergotamine-dependent vasoconstrictor responses.
- | Aimovig (erenumab) / Amgen, Novartis
Journal: Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries. (Pubmed Central) - Nov 2, 2020
Moreover, erenumab shows functional specificity as no interaction was observed with the relaxant responses to several vasodilators, nor the dihydroergotamine-dependent vasoconstrictor responses. Our findings demonstrate that erenumab, while not associated with vasoactive properties per se, specifically inhibits calcitonin gene-related peptide-induced relaxation of cranial arteries without impacting vasodilatory responses or contractile responses of endogenous or pharmacological vasoactive compounds.
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors - important studies on human isolated arteries. (Pubmed Central) - Nov 2, 2020
Our findings demonstrate that erenumab, while not associated with vasoactive properties per se, specifically inhibits calcitonin gene-related peptide-induced relaxation of cranial arteries without impacting vasodilatory responses or contractile responses of endogenous or pharmacological vasoactive compounds. No abstract available
- | Aimovig (erenumab) / Amgen, Novartis
Retrospective data, Journal: Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. (Pubmed Central) - Nov 2, 2020
P2, P3
No abstract available This pooled safety analysis revealed a favorable and stable adverse event profile over time for erenumab with more than three years of exposure.
- || Clinical, Journal: Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. (Pubmed Central) - Nov 2, 2020
Monoclonal antibodies inhibiting CGRP are effective in migraine prophylaxis with minimal adverse effects. Targeting CGRP is a novel clinical strategy in managing migraine.
- || Aimovig (erenumab) / Amgen, Novartis
Excited to see a @NICEComms committee meeting coming up on 4 Nov for the Aimovig appeal, following delays needed due to the covid crisis! @UK_headache @MigraineTrust @theABN_Info @MigraineAction @NatMigraineCtr #migraine #spoonie #disabilitytwitter #Neurology (Twitter) - Nov 1, 2020
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment closed: Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients (clinicaltrials.gov) - Oct 28, 2020
P4, N=621, Active, not recruiting, Sponsor: Amgen
Targeting CGRP is a novel clinical strategy in managing migraine. Recruiting --> Active, not recruiting
- | Retrospective data, Journal: Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. (Pubmed Central) - Oct 28, 2020
In addition to the acceptable withdrawal rates, serious adverse events were rare, and the severity of most adverse events was mild to moderate. Injection site reaction may be the major adverse event associated with galcanezumab.
- || Aimovig (erenumab) / Amgen, Novartis
@Amgen Should I take aimovig if I'm allergic to aimovig? (Twitter) - Oct 28, 2020
- | Aimovig (erenumab-aooe) / Amgen, Novartis
New P4 trial: REFORM: Registry for Migraine - Clinical Core (clinicaltrials.gov) - Oct 26, 2020
P4, N=1000, Recruiting, Sponsor: Danish Headache Center
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open: Efficacy of Erenumab on Functional Impact of Migraine (clinicaltrials.gov) - Oct 25, 2020
P4, N=54, Recruiting, Sponsor: Merle Diamond
Injection site reaction may be the major adverse event associated with galcanezumab. Not yet recruiting --> Recruiting
- || Aimovig (erenumab) / Amgen, Novartis
Clinical, Journal: Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. (Pubmed Central) - Oct 25, 2020
Erenumab showed consistent efficacy in episodic migraine patients who had failed prior preventive treatments and was well tolerated across subgroups. The data suggest prior patients with prior treatment failures have lower placebo response rates.
- ||| Aimovig (erenumab) / Amgen, Novartis
#GITwitter Has anyone come across amovig (erenumab-aooe) causing esophageal motility issues or delayed gastric emptying/gastroparesis ? I do know it could cause severe constipation @LindaNguyenMD @umfoodoc @WalterChanMD (Twitter) - Oct 21, 2020
- || Aimovig (erenumab) / Amgen, Novartis
It’s an anti-CGRP medication similar to Aimovig but Aimovig has not been approved for use in the NHS at the moment. (Twitter) - Oct 21, 2020
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion, Head-to-Head: HER-MES: Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine (clinicaltrials.gov) - Oct 20, 2020
P4, N=831, Completed, Sponsor: Novartis Pharmaceuticals
The data suggest prior patients with prior treatment failures have lower placebo response rates. Active, not recruiting --> Completed
- |||| Aimovig (erenumab-aooe) / Amgen, Novartis
Enrollment open, Trial completion date, Trial primary completion date: Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine (clinicaltrials.gov) - Oct 19, 2020
P4, N=340, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | Trial completion date: Jun 2022 --> Nov 2022 | Trial primary completion date: Jun 2022 --> Nov 2022
- ||| Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo
Enrollment open: A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist (clinicaltrials.gov) - Oct 19, 2020
P4, N=60, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Recruiting | Trial completion date: Jun 2022 --> Nov 2022 | Trial primary completion date: Jun 2022 --> Nov 2022 Not yet recruiting --> Recruiting
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Biomarker, New P4 trial: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab (clinicaltrials.gov) - Oct 18, 2020
P4, N=400, Recruiting, Sponsor: Danish Headache Center
- ||||| Aimovig (erenumab) / Amgen, Novartis
Clinical: Talking #CGRP role in #migraine with @daviddodick @Alberta_Pain #PainAB2020. Hypothalamic deactivation on folks where #erenumab is working. It’s not clear how the blood brain barrier impacts differently in individuals. #brilliant #migraineresearch (Twitter) - Oct 17, 2020